Evercore ISI Group Assumes Hyatt Hotels at In-Line
Evercore ISI Group analyst Duane Pfenningwerth assumes Hyatt Hotels (NYSE:H) with a In-Line rating.
Evercore ISI Group Assumes Diamondrock Hospitality at In-Line, Announces Price Target of $10
Evercore ISI Group analyst Duane Pfennigwerth assumes Diamondrock Hospitality (NYSE:DRH) with a In-Line rating and announces Price Target of $10.
EF Hutton Initiates Coverage On Hudson Technologies with Buy Rating, Announces Price Target of $11
EF Hutton analyst Chip Moore initiates coverage on Hudson Technologies (NASDAQ:HDSN) with a Buy rating and announces Price Target of $11.
B of A Securities Initiates Coverage On System1 with Buy Rating, Announces Price Target of $12
B of A Securities analyst Nat Schindler initiates coverage on System1 (NYSE:SST) with a Buy rating and announces Price Target of $12.
Loop Capital Initiates Coverage On Boyd Gaming with Buy Rating, Announces Price Target of $86
Loop Capital analyst Daniel Adam initiates coverage on Boyd Gaming (NYSE:BYD) with a Buy rating and announces Price Target of $86.
Wells Fargo Initiates Coverage On G-III Apparel Group with Equal-Weight Rating, Announces Price Target of $20
Wells Fargo analyst Ike Boruchow initiates coverage on G-III Apparel Group (NASDAQ:GIII) with a Equal-Weight rating and announces Price Target of $20.
Goldman Sachs Initiates Coverage On Affirm Holdings with Neutral Rating, Announces Price Target of $22
Goldman Sachs analyst Michael Ng initiates coverage on Affirm Holdings (NASDAQ:AFRM) with a Neutral rating and announces Price Target of $22.
Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I.
Why This Small-Cap Stock Is Gaining More Than 10% Today?
Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18. Immuneering’s lead candidate, IMM-1-104, an…
